Corona Remedies IPO Opens on Monday (Dec 8): Key Details, Price Band, and Financial Performance

Corona Remedies IPO is set to open for subscription on December 8, 2025, with the issue closing on December 10, 2025. 

The pharmaceutical company, known for its chronic and acute therapy portfolio, is launching a ₹655.37 crore book-built issue, entirely through an Offer for Sale (OFS) of 0.62 crore equity shares. 

Since the IPO comprises only an OFS, no funds will flow into the company; instead, existing shareholders will dilute their stake.

The price band for the IPO has been fixed at ₹1,008–₹1,062 per share, and retail investors can apply with a minimum lot size of 14 shares, requiring a basic investment of ₹14,868 at the upper end of the price band.

Corona Remedies – Key Financial Metrics

Revenue Growth and Market Position

Corona Remedies has displayed consistent revenue growth across financial years. Revenue from operations rose from ₹8,840.50 million in FY23 to ₹10,144.74 million in FY24, and further to ₹11,964.15 million in FY25. For the quarter ended June 30, 2025, the company reported ₹3,465.42 million in revenue.

The company’s domestic footprint remains dominant, with over 96% of revenue consistently derived from the Indian market. International operations contributed a modest 3.38–3.67% during FY23 to FY25.

Profitability Metrics Show Robust Improvement

Corona Remedies has posted healthy margin expansion over the years. Gross profit grew from ₹6,730.96 million in FY23 to ₹9,599.04 million in FY25, with gross margin rising steadily to 81.02% in Q1 FY26.

EBITDA improved sharply to ₹2,459.13 million in FY25, with margins touching 20.55%, while profit after tax surged to ₹1,494.34 million, a 65.11% YoY jump in FY25.

Return ratios such as RoCE (41.32%) and RoE (27.50%) in FY25 underline the company’s operational efficiency. Net working capital days remained well-managed at 24.17 days in FY25.

Also Read: How to Buy NSE Unlisted Shares in India?

Conclusion

With financial performance, expanding margins, and consistent domestic market strength, the Corona Remedies IPO is likely to attract significant investor interest. However, since the issue is entirely an OFS, investors should assess valuations and long-term growth prospects before subscribing. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.